PDF file: 441-2672_VISP_Vaccine_injury_support_program.pdf
OPQ ID: 441-2672
Session: 441
Question number: Q-2672
Sessional paper: Q-2672
Title: VISP, Vaccine injury support program
Short description: 
Topic: vaccines
Identified concern: 
Keywords: 
Agencies: HC, PHAC
Date asked: 2024-05-02
Date tabled: 
Submitted by: Mrs. Wagantall (Yorkton—Melville)
Reply by: Minister of Health
Responded by: Mr. Yasir Naqvi
Pages: 4
Status: not processed
Alert: yellow
Questions asked: 15
Questions answered: 8
Percent responded: 53%
Referenced sources: World Health Organization
Referenced links: https://vaccineinjurysupport.ca/en/program-statistics.The, https://www.quebec.ca/en/health/advice-andprevention/vaccination/vaccine-injury-compensation-program#c3895X
Official link: https://www.google.com/search?q=Q-2672+ourcommons.ca
PDF URL: https://ivim.ca/foi/opq/r/441-2672_VISP_Vaccine_injury_support_program.pdf
TXT URL: https://ivim.ca/foi/opq/r/441-2672.txt
Original filename: Q-2672_HC, VISP, Vaccine injury support program.pdf
Local source path: C:\Users\Dmitry\Documents\CODES\OPQ-App\data-raw\OPQ\ALL OPQ TO DATE\2022\Q-2672_HC, VISP, Vaccine injury support program.pdf
Machine extracted at: 2026-06-30 12:58:27

References / links:
- https://vaccineinjurysupport.ca/en/program-statistics.The
- https://www.quebec.ca/en/health/advice-andprevention/vaccination/vaccine-injury-compensation-program#c3895X
- World Health Organization

Machine notes:
(none)

Question text preview:
With respect to Canada’s Vaccine Injury Support Program (VISP): (a) how many claims have been filed to the program from December 8,
2020, to present day, broken down by age group;
(b) how many of those claims have been approved, broken down by age group;
(c) of the approved claims, what have been the diagnoses and their frequencies, broken down by age group, date approved, and the corresponding
COVID-19 vaccines that were administered;
(d) of the approved claims, what are the percentages of Canadians who received (i) the
AstraZeneca COVID-19 vaccine, (ii) the J&J COVID-19 vaccine, (iii) any COVID-19 vaccine produced by Pfizer-BioNTech, (iv) any COVID19 vaccine produced by Moderna, (v) a combination of COVID-19 vaccines;
(e) how many persons have received compensation to date through the VISP;
(f) what is the total compensation to date given to vaccine-injured Canadians;
(g) what is the age of the youngest person who received funding support approval through the VISP, and their associated diagnosis;
(h) for all death claims, (i) what is the total number of death claims that have been filed to VISP, (ii) of the total, what have been the underlying causes of death, aside from the vaccine and their frequencies, (iii) how many filed death claims have been approved by the VISP and their corresponding diagnosis and vaccine status;
(i) did the VISP require autopsies prior to approving a death claim;
(j) if the answer to (i) is affirmative, what immunohistochemistry requirements does the VISP specify for these autopsies;
(k) when denied, how many persons have appealed their claim and how many have been successful;
(l) regarding the determination of causality of the adverse event in relation to a COVID-19 vaccine, (i) what is the standard criteria, (ii) does the Medical Review Board take into consideration the Bradford Hill criteria;
(m) what are the professional qualifications of each member on the Medical Review Board; and (n) who are the professionals on the Medical Review Board?